Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY
Recorded on October 2, 2020
Minimal/measurable residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers. Tune in today!
Gail J. Roboz, MD
Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, NY
This podcast episode is supported by Amgen.
Podcast: Play in new window | Download (Duration: 45:10 — 41.4MB)